Surrey Heartlands

Joint Formulary & PAD

Tolterodine - Overactive bladder (adults)

You are here : Home > Formulary Search > Tolterodine - Overactive bladder (adults)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Immediate release tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
1st line in patients with renal impairment
 

Status 2

Non Formulary
Formulations :
  • Modified release tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NFD1
Restrictions / Comments :
Important

Switch to solifenacin (or formulary alternative) recommended

Documentation

Guidelines (Local)
Selection tool for OAB treatments - Nov 2024
Webpage
NICE NG123 Urinary-incontinence-and-pelvic-organ-prolapse-in-women
Webpage
NICE Clinical guideline [CG97] : Lower urinary tract symptoms in men: management
Webpage
LUTS in Men - Management of Overactive Bladder - CKS guidance
Webpage
Urinary incontinence in women - CKS guidelines
Patient resource
Leaflet-for-trial-of-stopping-OAB-drugs - anticholinergics - Mar 24

PAD Profile

ChemicalSubstance :
Tolterodine
Indication :
Overactive bladder (adults)
Group Name :
Keywords :
antimuscarinics, OAB, urge incontinence, urinary incontinence, urinary frequency, LUTS, urinary urgency, anticholinergics,
Brand Names Include :
Detrusitol, Mariosea XL, Neditol XL, Tolterma XL, Blerone XL
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Overactive bladder (adults)
Supporting Documents :
6
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Tolterodine is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Overactive bladder (adults).

Committee Recommendations (2)

06 Mar 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC supports patients in trialling a treatment break of their overactive bladder medicines.

A "Leaflet for trial of stopping anticholinergics" can be found in the documents section below.

05 Jul 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Solifenacin is the 1st line treatment option.

Tolterodine immediate release is an alternative 1st line treatment option in patients with renal impairment (GFR <30mls/min)) and can be commenced at lower doses.

See Selection Tool for locally agreed OAB treatment options

Tolterodine modified release tablets are non-formulary. It was agreed by the APC that tolterodine MR can be switched to solifenacin (or an alternative formulary option) if approrpiate.